Biocon

BSE: 532523 | NSE: BIOCON | ISIN: INE376G01013 | SECTOR: Biotechnology & Drugs

₹ 301.80

-3.40 (-1.11%)
06 May 2024, 03:54 PM IST
View all metrics

Key Metrics

Influencer Count

-

Simple Moving Averages

DaysBSENSE

5302.08302.08
10283.90283.94
20277.72277.73
50272.20272.20
100268.05268.05
300260.05260.07

News

View all

Company Description

Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

Company Officers